exemestane


Also found in: Medical, Wikipedia.
Related to exemestane: letrozole, Fulvestrant
Translations

exemestane

n exemestano
References in periodicals archive ?
Bliss and her colleagues initiated the Intergroup Exemestane Study of more than 4,700 patients from 37 countries and 366 centers worldwide.
Two nonsteroidal aromatase inhibitors, anastrozole and letrozole, are approved in the United States as first- or second-line treatment of hormone receptor-positive metastatic breast cancer, and one steroidal aromatase inactivator, exemestane, is approved for hormone therapy for women with metastatic breast cancer after disease progression or after antiestrogen therapy.
5 July 2011 - Swiss-based drugmaker Novartis AG (VTX: NOVN) said today that an interim analysis of a pivotal Phase III study showed Afinitor (everolimus) tablets in combination with exemestane significantly extended progression-free survival (PFS), or time without tumour growth, when compared to placebo plus exemestane in women with advanced breast cancer.
In 2004, based on results of Intergroup Exemestane Study (IES) the TEAM trial design was revised; the tamoxifen arm was converted into a tamoxifen/AROMASIN sequencing arm.
Tenders are invited for Exemestane 25Mg Tab In Strip
11 December 2009 - US-based pharmaceutical company Pfizer Inc (NYSE: PFE) reported yesterday results from an exploratory analysis of the Intergroup Exemestane Study (IES) at a median follow-up of 91 months in estrogen-receptor positive (ER+) or estrogen-receptor unknown (ER-unknown) women that looked at breast cancer free survival (BCFS) and censored deaths that occurred prior to breast cancer relapse.
Based upon the highly favorable IES data, Pfizer announced it has submitted a supplemental New Drug Application seeking Food and Drug Administration approval for exemestane as adjuvant therapy in postmenopausal women with hormone receptor positive early-stage breast cancer.
Switching to exemestane therapy after 2-3 years of tamoxifen treatment improves disease-free survival in postmenopausal women with breast cancer, according to Dr.
ATLANTA -- Postmenopausal women with early-stage hormone-receptive breast cancer who have done well on 2-3 years of tamoxifen therapy have improved survival if they are switched to exemestane midway through their hormonal treatment, researchers reported at the annual meeting of the American Society of Clinical Oncology.
The study, which involved 4,742 women treated in 37 countries, was halted in December; its results were announced early after an interim analysis of the data revealed that switching to exemestane yielded an absolute disease-free survival benefit of nearly 5%, compared with continuing tamoxifen.
There is some evidence for a more favorable effect upon bone for steroidal aromatase inhibitors such as exemestane, which has a mild androgenic effect.
His research and publications include: Randomized Phase III Trial Comparing 16 to 18 Weeks of Neoadjuvant Exemestane (25 mg daily), Letrozole (2.